Yahoo Finance

BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $54 from $55 and keeps a Buy rating on the shares. The firm sees Agios’ story “gaining traction over the next 12 months” and cites slightly reduced outer-year revenue expectations, offset by reduced expenses, for its revised target on the shares.

Maximize Your Portfolio with Data Driven Insights:

• Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.

• Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on AGIO:

• AGIO Upcoming Earnings Report: What to Expect?

• Agios Pharma Sets Milestones for Rare Disease Growth

• Agios Pharmaceuticals announces key 2025 milestones, catalysts through 2026

• Agios Pharmaceuticals announces FDA accepted sNDA for PYRUKYND

• Agios Pharmaceuticals price target lowered to $55 from $60 at BofA